Eleven Brand/Generic Drug Patent Settlements Reported To FTC Since January
This article was originally published in The Pink Sheet Daily
Executive Summary
None of those settlements involved “reverse payments,” FTC staff attorney Kades says. In total, 17 agreements have been reported to FTC since January.
You may also be interested in...
Waxman/Hatch Changes Make “Reverse Payments” Less Likely, FTC Says
The Waxman/Hatch reforms included in the 2003 Medicare Modernization Act make "reverse payment" settlements of patent litigation less likely, the Federal Trade Commission says in a Supreme Court filing.
Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.
‘Frontline’ Essential Workers, Persons 75 Years And Older Prioritized For Second Phase Of COVID Vaccination
Essential workers who cannot work remotely and have high levels of interaction with the public, and individuals ≥75 years old, should get vaccinated ahead of those 65-74 years old and those with comorbid conditions, CDC Advisory Committee on Immunization Practices recommends.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: